REVEAL AF: Incidence of AF in High Risk Patients

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Medtronic Cardiac Rhythm and Heart Failure Identifier:
First received: November 12, 2012
Last updated: September 12, 2016
Last verified: September 2016
This study is to determine, through continuous monitoring with the Reveal implantable cardiac monitor (ICM), the incidence of atrial fibrillation (AF) in patients suspected to be at high risk for having AF and to understand how physicians manage these patients after AF has been detected. This study will also seek to identify what patient characteristics are most predictive of developing AF.

Condition Intervention
Atrial Fibrillation
Device: REVEAL Implantable cardiac monitor

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Screening
Official Title: Reveal XT Implantable Cardiac Monitor

Resource links provided by NLM:

Further study details as provided by Medtronic Cardiac Rhythm and Heart Failure:

Primary Outcome Measures:
  • Time to first Atrial Fibrillation lasting six or more minutes. [ Time Frame: Implant to 18 month follow-up visit ]
    Each arrhythmic episode detected by the patient's Reveal device will be reviewed to determine if it is 1) an actual Atrial Fibrillation episode, and (2) are at least 6 minutes in duration. The time to the first such episode in which both criteria are met will be the endpoint for each patient.

Secondary Outcome Measures:
  • Predictors of Atrial Fibrillation [ Time Frame: Time from implant to date of last stored available implanted device data (maximum of 30 months) ]
    Atrial Fibrillation will be defined as in the primary outcome. Baseline characteristics including demographics, medical history, and biomarkers at enrollment will be tested for their association with a patient's risk of developing atrial fibrillation.

  • Actions taken in response to awareness of atrial fibrillation [ Time Frame: Time from first identified episode of atrial fibrillation to study exit (maximum of 30 months) ]
    Clinical actions taken in response to clinician awareness of a patient's atrial fibrillation onset or progression will be summarized

Enrollment: 450
Study Start Date: October 2012
Estimated Study Completion Date: April 2017
Estimated Primary Completion Date: January 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
REVEAL Implantable cardiac monitor Device: REVEAL Implantable cardiac monitor


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient meets the approved indications to receive the Reveal ICM
  • Patient is suspected, based on symptomatology and/or demographics, of having atrial fibrillation or at high risk of having AF, as determined by the clinical investigator
  • Patient has a CHADS2 score ≥ 3 OR has a CHADS2 score = 2 WITH at least one of the following documented: Renal impairment (GFR 30-60 ml/min, sleep apnea, coronary artery disease, or chronic obstructive pulmonary disease. Note: stroke/TIA criterion as part of the CHADS2 score for this trial is limited to either an ischemic stroke or TIA, which occurred MORE THAN one year prior to enrollment.
  • Patient is 18 years of age or older
  • Patient has a life expectancy of 18 months or more
  • Patient, or legally authorized representative, is willing to sign and date the consent form
  • Patient is willing and able to be remotely monitored (i.e., eligible for enrollment into the Medtronic CareLink Network)

Exclusion Criteria:

  • Patient has a documented history of AF or atrial flutter
  • Patient had an ischemic stroke or TIA within past year prior to enrollment
  • Patient has a history of a hemorrhagic stroke
  • Patient is currently implanted with an IPG, ICD, CRT-P, or CRT-D device
  • NYHA Class IV Heart Failure patient
  • Patient had heart surgery within previous 90 days prior to enrollment
  • Patient had an MI within the previous 90 days prior to enrollment
  • Patient is taking chronic immuno-suppressant therapy
  • Patient is taking an anti-arrhythmic drug
  • Patient is contraindicated for long term anticoagulation medication
  • Patient is taking a long-term anticoagulation medication
  • Any concomitant condition which, in the opinion of the investigator, would not allow safe participation in the study (e.g., drug addiction, alcohol abuse, emotional / psychological diagnosis)
  • Patient is enrolled in another study that could confound the results of this study, without documented pre-approval from Medtronic study manager
  • Patient has a creatinine clearance <30 ml/min or is on dialysis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01727297

  Hide Study Locations
United States, Alabama
Birmingham, Alabama, United States
United States, California
Fresno, California, United States
Healdsburg, California, United States
United States, Delaware
Seaford, Delaware, United States
United States, Florida
Bradenton, Florida, United States
Gainesville, Florida, United States
Kissimmee, Florida, United States
St. Petersburgh, Florida, United States
United States, Indiana
Bloomington, Indiana, United States
Munster, Indiana, United States
United States, Kansas
Kansas City, Kansas, United States
United States, Maryland
Salisbury, Maryland, United States
United States, Minnesota
Minneapolis, Minnesota, United States
United States, Mississippi
Jackson, Mississippi, United States
United States, Missouri
Springfield, Missouri, United States
United States, Nebraska
Omaha, Nebraska, United States
United States, New Jersey
Englewood, New Jersey, United States
Ridgewood, New Jersey, United States
Voorhees, New Jersey, United States
United States, New York
New York, New York, United States
United States, North Carolina
Gastonia, North Carolina, United States
United States, Ohio
Youngstown, Ohio, United States
United States, Oklahoma
Oklahoma City, Oklahoma, United States
United States, Oregon
Salem, Oregon, United States
United States, Pennsylvania
Allentown, Pennsylvania, United States
Wynnewood, Pennsylvania, United States
United States, Rhode Island
Wakefield, Rhode Island, United States
United States, South Carolina
Anderson, South Carolina, United States
United States, Tennessee
Chattanooga, Tennessee, United States
Knoxville, Tennessee, United States
Memphis, Tennessee, United States
United States, Texas
Dallas, Texas, United States
Plano, Texas, United States
The Woodlands, Texas, United States
United States, Wisconsin
Waukesha, Wisconsin, United States
Graz, Austria
Linz, Austria
Coburg, Germany
Düsseldorf, Germany
Gottingen, Germany
Hamburg, Germany
Lünen, Germany
Tübingen, Germany
Monza, Italy
Nergrar, Italy
Torino, Italy
Eindhoven, Netherlands
Nieuwegein, Netherlands
Ljubljana, Slovenia
Tarragona, Spain
Sponsors and Collaborators
Medtronic Cardiac Rhythm and Heart Failure
  More Information

Responsible Party: Medtronic Cardiac Rhythm and Heart Failure Identifier: NCT01727297     History of Changes
Other Study ID Numbers: REVEAL AF 
Study First Received: November 12, 2012
Last Updated: September 12, 2016

Additional relevant MeSH terms:
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes processed this record on January 19, 2017